You are now leaving XifaxanHE.com

Thank you for visiting XifaxanHE.com. By clicking OK, you will be taken to a website or sites where our Privacy Policy and other rules do not apply. Salix Pharmaceuticals does not possess editorial control over the content of the information on such website(s) and therefore does not warrant their accuracy and completeness. You are solely responsible for interactions with such website(s).

OKCancel

HE MANAGEMENT

Recommended by experts

Once an overt hepatic encephalopathy (HE) episode occurs, there is a high risk for more episodes. These are called recurrences.

That is why HE experts recommend ongoing management to help reduce the risk of an overt HE recurrence. After a recurrence, experts recommend adding XIFAXAN to lactulose for ongoing management.

The safety and efficacy of XIFAXAN in HE patients has not been studied for longer than 6 months in clinical trials.
If patients recover a significant amount of liver function, they may be able to discontinue HE therapy.

REVIEW THE RISKS OF OVERT HE RECURRENCE

Taking XIFAXAN daily as prescribed helps reduce the risk of overt HE recurrence in adults.

LEARN MORE ABOUT XIFAXAN

Round button with nurse icon that reads Enroll in H.E.L.P. for support Round button with nurse icon that reads Enroll in H.E.L.P. for support

*Eligibility criteria, terms and conditions apply.

It can be challenging to manage overt HE. That's why ongoing help is available for adults

living with a history of HE and their caregivers—the HE Living Program (H.E.L.P.).

INDICATION

XIFAXAN® (rifaximin) 550 mg tablets are indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults.

IMPORTANT SAFETY INFORMATION - XIFAXAN (rifaximin) 550 mg tablets in HE

  • XIFAXAN is not for everyone. Do not take XIFAXAN if you have a known hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any of the components in XIFAXAN.
  • If you take antibiotics, like XIFAXAN, there is a chance you could experience diarrhea caused by an overgrowth of bacteria (C. difficile). This can cause symptoms ranging in severity from mild diarrhea to life-threatening colitis. Contact your healthcare provider if your diarrhea does not improve or worsens.
  • XIFAXAN has not been studied in people with MELD scores over 25 and only 8.6% of people in the controlled study had MELD scores over 19. There is an increased chance that XIFAXAN will spread through your body if you have more severe hepatic dysfunction. Therefore, if you have severe hepatic impairment, which is a Child-Pugh score of C, you should talk to your healthcare provider before taking XIFAXAN.
  • Tell your doctor if you are taking drugs called P-glycoprotein inhibitors (such as cyclosporine) because using these drugs with XIFAXAN may lead to an increase in the amount of XIFAXAN absorbed by your body.
  • If you are pregnant, planning to become pregnant, or nursing, talk to your healthcare provider before taking XIFAXAN because it is unknown if XIFAXAN can harm an unborn baby or nursing infant.
  • In the clinical study, the most common side effects in HE associated with XIFAXAN 550 mg tablets—occurring in at least 10% of people receiving XIFAXAN—were peripheral edema (swelling, usually in the ankles or lower limbs), nausea (feeling sick to your stomach), dizziness, fatigue (feeling tired), and ascites (a buildup of fluid in the abdomen).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For product information, adverse event reports, and product complaint reports, please contact:

Salix Product Information Call Center
Phone: 1-800-508-0024
Fax: 1-510-595-8183
Email: valeantmc@dlss.com

Please click here for full Prescribing Information for XIFAXAN.

HE Living Program logo

A 24/7 helpline staffed by nurses

Reminder telephone calls about prescription refills and doctor visits

Additional information about HE and XIFAXAN

Tools to help plan for what comes after a hospitalization

ENROLL NOW

See MoreImportant Safety Information
See LessImportant Safety Information

INDICATION

XIFAXAN® (rifaximin) 550 mg tablets are indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults.

IMPORTANT SAFETY INFORMATION - XIFAXAN (rifaximin) 550 mg tablets in HE

  • XIFAXAN is not for everyone. Do not take XIFAXAN if you have a known hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any of the components in XIFAXAN.
  • If you take antibiotics, like XIFAXAN, there is a chance you could experience diarrhea caused by an overgrowth of bacteria (C. difficile). This can cause symptoms ranging in severity from mild diarrhea to life-threatening colitis. Contact your healthcare provider if your diarrhea does not improve or worsens.
  • XIFAXAN has not been studied in people with MELD scores over 25 and only 8.6% of people in the controlled study had MELD scores over 19. There is an increased chance that XIFAXAN will spread through your body if you have more severe hepatic dysfunction. Therefore, if you have severe hepatic impairment, which is a Child-Pugh score of C, you should talk to your healthcare provider before taking XIFAXAN.
  • Tell your doctor if you are taking drugs called P-glycoprotein inhibitors (such as cyclosporine) because using these drugs with XIFAXAN may lead to an increase in the amount of XIFAXAN absorbed by your body.
  • If you are pregnant, planning to become pregnant, or nursing, talk to your healthcare provider before taking XIFAXAN because it is unknown if XIFAXAN can harm an unborn baby or nursing infant
  • In the clinical study, the most common side effects in HE associated with XIFAXAN 550 mg tablets—occurring in at least 10% of people receiving XIFAXAN—were peripheral edema (swelling, usually in the ankles or lower limbs), nausea (feeling sick to your stomach), dizziness, fatigue (feeling tired), and ascites (a buildup of fluid in the abdomen).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch/ or call 1-800-FDA-1088.

For product information, adverse event reports, and product complaint reports, please contact:

Salix Product Information Call Center
Phone: 1-800-508-0024
Fax: 1-510-595-8183
Email: valeantmc@dlss.com

Please click here for full Prescribing Information for XIFAXAN.